diabetes and systolic blood pressure), we also calculated the instrumental variable estimates of genetically determined betas and odds ratios by using a 1-sample MR approach. For these traits, the same strategy as described for 2-sample MR analyses was applied. Diagram showing the MR assumptions for a valid instrument variable (IV) : IV must be associated with the exposure (solid line) but independent from confounders of the exposureoutcome association and independent of the outcome conditional on the exposure and confounders (dotted lines marked with a cross), according to Bowden et al.
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Instrument variables used for Mendelian randomization
The genetic variants used were dosages from the UK Biobank's imputation dataset (version 2). We selected the lead genome-wide significant SNPs (P values < 5 x10 -8 ) associated
with each risk factor from the most recent and largest GWAS on these exposures (Supplementary Table S3 ). For each risk factor, we grouped the selected SNPs by LD (r²> 0.01) and kept only the SNP with the lowest P value in each group, to ensure SNPs independence. For all the traits other than BMI, we performed the analyses both with and without SNPs that were also associated with BMI (P value< 0.05), to avoid pleiotropy, as BMI was early shown to be robustly causative. Detailed information of SNP selection for the different traits and the associations for these SNPs with BMI are given in Supplementary   Tables S5-S13 .
Mendelian randomization analyses
The mendelian randomization (MR) approach used in this study made the following assumptions (Supplementary Figure S1 ): the genetic instruments for the exposures were all significantly associated with the risk markers; the genetic instruments for the exposures were not associated with confounding factors that bias conventional associations between risk factors and OA; the genetic instruments for the exposures were not related to OA via other effects than their corresponding risk factor. For all MR methods, the causal effects of each risk factor on different OA locations were analysed in age and sex adjusted models. For systolic blood pressure, we further adjusted for AHM use or excluded AHM users from the analyses.
Two-sample Mendelian randomization
We used different MR methods to assess causal relations between the candidate risk factors and OA as outcome. Firstly, we assessed the effects of the SNPs upon the different OA outcomes, weighting the effect of each SNP by the magnitude of its effect upon its corresponding exposure. For the 2-sample MR methods, the effect estimates for exposures were taken from the selected GWAS for each risk factor [1] ( Supplementary Table S3 ). Four MR methods were performed for each causal analysis. As the primary MR analyses, we used combined weighted estimates by an inverse-variance weighted (IVW) approach using fixed or random effects depending on Cochran's Q statistic test of heterogeneity. We then used the MREgger method as a sensitivity analysis to avoid possible uncontrolled pleiotropy [2] . It uses a weighted regression with an unconstrained intercept to regress the effect sizes of variant risk factor associations. It thus removes the assumption that all genetic variants are valid instrumental variables. In addition, in further sensitivity analyses we used the penalized weighted median MR method and the weighted median MR methods. As BMI is a known confounder and shown to be causally associated with OA, we systematically performed additional sensitivity analyses restricting the instrument variables to the SNPs that were not associated with BMI.
Power calculation
Calculations were performed to test whether our study was adequately powered to detect a significant change in the OA outcomes with the inverse-variance weighted method. For each trait and OA definition, we used the variance explained by the instruments variables (R²) reported in the GWAS publications listed in Supplementary Table S3, the proportion of OA cases and the sample size, to estimate the power to detect different OR of 1.10, 1.15, 1.20, 1.50 and 2.0 (alpha = 0.05; http://cnsgenomics.com/shiny/mRnd/) [3] . For LS-BMD, as the R² value was not available in the GWAS publication, we used the value reported in another study [4] (calculated from the Study of Osteoporotic Fractures). For HLD-cholesterol, LDL-cholesterol and triglycerides, we used the values from the selected GWAS [5] in addition to those of a previous published GWAS from the same consortium [6] . The F-statistics reflects the strength of the genetic instruments for each OA definition (Supplementary Table S4 ).
Supplemental Figures Figure S1: Summary of the Mendelian randomization assumptions
Diagram showing the MR assumptions for a valid instrument variable (IV) : IV must be associated with the exposure (solid line) but independent from confounders of the exposureoutcome association and independent of the outcome conditional on the exposure and confounders (dotted lines marked with a cross), according to Bowden et al. [2] . For each location, OR and 95% confidence intervals for the risk of OA are represented for each factor using the 2 sample MR inverse-variance weighted method for systolic blood pressure (SBP, per SD increase), excluding antihypertensive medications users. Bars in black represent MR analyses using all instrument variables (IV), and bars in red represent sensitivity analyses when excluding the IV that were associated with BMI (P value< 0.05). Total number of subjects is 305 170 with 32 668 all OA, 13 009 knee OA, 8 117 hip OA and 1 646 hand OA cases.
OA: osteoarthritis; BMI: Body mass index; IV: instrument variable. For Triglycerides betas are given as SD of LDL-cholesterol per effect allele For BMI betas are given as SD of BMI per effect allele EA: effect allele; OA: other allele; EAF: effect allele frequency; UKBB: UK Biobank; BMI: body mass index; LD: linkage desequilibrium 
